KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Debt to Equity (2016 - 2026)

AbbVie has reported Debt to Equity over the past 14 years, most recently at -$19.03 for Q4 2025.

  • Quarterly Debt to Equity fell 194.25% to -$19.03 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$19.03 through Dec 2025, down 194.25% year-over-year, with the annual reading at -$19.03 for FY2025, 194.25% down from the prior year.
  • Debt to Equity was -$19.03 for Q4 2025 at AbbVie, up from -$24.58 in the prior quarter.
  • Over five years, Debt to Equity peaked at $45.23 in Q1 2025 and troughed at -$470.72 in Q2 2025.
  • The 5-year median for Debt to Equity is $4.76 (2022), against an average of -$17.99.
  • The largest YoY upside for Debt to Equity was 391.81% in 2025 against a maximum downside of 4645.63% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $4.16 in 2021, then fell by 12.01% to $3.66 in 2022, then skyrocketed by 56.06% to $5.71 in 2023, then soared by 253.55% to $20.19 in 2024, then tumbled by 194.25% to -$19.03 in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Debt to Equity are -$19.03 (Q4 2025), -$24.58 (Q3 2025), and -$470.72 (Q2 2025).